Protective immunity in lyme borreliosis

E. Fikrig, F. S. Kantor, Stephen W Barthold, R. A. Flavell

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne illness in the USA. Although early infection can be treated with antibiotics, the initial diagnosis is difficult and late disease may be recalcitrant to therapy. A vaccine against Lyme disease is therefore needed, and murine models of Lyme borreliosis have facilitated its development. In this review, Erol Fikrig, Fred Kantor, Stephen Barthold and Richard Flavell focus on the use of Borrelia surface antigens as vaccine candidates for Lyme disease.

Original languageEnglish (US)
Pages (from-to)129-131
Number of pages3
JournalParasitology Today
Volume9
Issue number4
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Lyme Disease Vaccines
Borrelia burgdorferi
Lyme Disease
Immunity
Borrelia
Surface Antigens
Anti-Bacterial Agents
Infection
Therapeutics

ASJC Scopus subject areas

  • Parasitology

Cite this

Protective immunity in lyme borreliosis. / Fikrig, E.; Kantor, F. S.; Barthold, Stephen W; Flavell, R. A.

In: Parasitology Today, Vol. 9, No. 4, 1993, p. 129-131.

Research output: Contribution to journalArticle

Fikrig, E. ; Kantor, F. S. ; Barthold, Stephen W ; Flavell, R. A. / Protective immunity in lyme borreliosis. In: Parasitology Today. 1993 ; Vol. 9, No. 4. pp. 129-131.
@article{821f5c3b006942b5bcac386402df08c8,
title = "Protective immunity in lyme borreliosis",
abstract = "Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne illness in the USA. Although early infection can be treated with antibiotics, the initial diagnosis is difficult and late disease may be recalcitrant to therapy. A vaccine against Lyme disease is therefore needed, and murine models of Lyme borreliosis have facilitated its development. In this review, Erol Fikrig, Fred Kantor, Stephen Barthold and Richard Flavell focus on the use of Borrelia surface antigens as vaccine candidates for Lyme disease.",
author = "E. Fikrig and Kantor, {F. S.} and Barthold, {Stephen W} and Flavell, {R. A.}",
year = "1993",
doi = "10.1016/0169-4758(93)90176-G",
language = "English (US)",
volume = "9",
pages = "129--131",
journal = "Trends in Parasitology",
issn = "1471-4922",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Protective immunity in lyme borreliosis

AU - Fikrig, E.

AU - Kantor, F. S.

AU - Barthold, Stephen W

AU - Flavell, R. A.

PY - 1993

Y1 - 1993

N2 - Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne illness in the USA. Although early infection can be treated with antibiotics, the initial diagnosis is difficult and late disease may be recalcitrant to therapy. A vaccine against Lyme disease is therefore needed, and murine models of Lyme borreliosis have facilitated its development. In this review, Erol Fikrig, Fred Kantor, Stephen Barthold and Richard Flavell focus on the use of Borrelia surface antigens as vaccine candidates for Lyme disease.

AB - Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne illness in the USA. Although early infection can be treated with antibiotics, the initial diagnosis is difficult and late disease may be recalcitrant to therapy. A vaccine against Lyme disease is therefore needed, and murine models of Lyme borreliosis have facilitated its development. In this review, Erol Fikrig, Fred Kantor, Stephen Barthold and Richard Flavell focus on the use of Borrelia surface antigens as vaccine candidates for Lyme disease.

UR - http://www.scopus.com/inward/record.url?scp=0027512812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027512812&partnerID=8YFLogxK

U2 - 10.1016/0169-4758(93)90176-G

DO - 10.1016/0169-4758(93)90176-G

M3 - Article

C2 - 15463734

AN - SCOPUS:0027512812

VL - 9

SP - 129

EP - 131

JO - Trends in Parasitology

JF - Trends in Parasitology

SN - 1471-4922

IS - 4

ER -